Showcase Your RAS Research To 80+ Industry Leaders – Deadline Approaching

With just three weeks until the RAS- Targeted Drug Discovery Summit Europe, don’t miss this unique opportunity to present your research to 80+ attendees from Europe’s large pharma and biotech organisations committed to finally drugging the “undruggable” RAS.

Companies already confirmed include:

Allinky Biopharma – Aro Biotherapeutics – Astex Therapeutics – Bayer – Boehringer Ingelheim – Elicio Therapeutics – Italian Institute of Technology – Kanaph Therapeutics – Lawrence Livermore National Laboratory – National Cancer Research Centre Spain – Netherlands Cancer Institute – Oblique Therapeutics – Onconova Therapeutics – Pharos I&BT – PhoreMost – PolyProx Therapeutics – Revolution Medicines – Ridgeline Therapeutics – Sanofi – Targovax – The Francis Crick Institute – University of Luxembourg – University of Manchester – Vernalis – X-Chem Pharmaceuticals

 Want to add your name to the list and join your community? Register here.

** Poster Session – Deadline Approaching **

Don’t miss this unique opportunity to showcase your latest anti-RAS discovery and development efforts to an engaged audience of 80+ thought leaders. Present a poster to gain feedback from senior representatives within the industry to optimize your future research.

We have limited availability on the number of posters that can be presented, so we encourage participants to submit their entry early to avoid disappointment.

If you would like to share your research, please submit a title and abstract here. All poster abstracts are subject to approval by the conference organisers and must be submitted in conjunction with the purchase of a valid ticket. Buy your ticket online.

Important Information:

Deadline for submission is Friday 14 February. Late entries will not be accepted.

Register quoting VIP Code 16119PHP to save 10% off your ticket. Visit the website to see all pricing information, discounts and deadlines: https://ter.li/1131vy